Mucolipidosis II (I-Cell Disease)
A severe, early-onset inherited disorder of lysosomal enzyme trafficking caused by GNPTAB gene mutations, leading to multisystem skeletal, developmental, and organ involvement from infancy.
- GNPTAB Genetic Testing
- Multidisciplinary Specialist Review
- Early Supportive Care Planning
- Most Common Onset
- Prenatal to Early Infancy
- Inheritance
- Autosomal Recessive (GNPTAB Gene)
- Estimated Incidence
- Very Rare (<1 in 100,000 Births)
- Advanced Therapies
- HSCT in Select Cases (Investigational Focus)
Condition Overview
Mucolipidosis II, also called I-cell disease, is a severe inherited disorder caused by mutations in the GNPTAB gene, which encodes part of the enzyme complex responsible for tagging lysosomal enzymes so they reach their correct destination inside the cell. Without proper tagging, multiple lysosomal enzymes are misrouted and secreted out of the cell, leading to widespread accumulation of undegraded material — visible under the microscope as inclusion bodies, which gave the condition its name.
I-cell disease typically presents prenatally or in early infancy with skeletal abnormalities, growth failure, and characteristic coarse facial features, with multisystem involvement that can include the heart, respiratory system, and skeleton.
Because the condition is severe and presents very early, prompt referral to a metabolic genetics and multidisciplinary care team is important for both diagnosis confirmation and early supportive planning.
Types and Subtypes
Mucolipidosis II is generally recognized as a single severe clinical entity, distinguished from the related, milder Mucolipidosis III by the degree of residual enzyme trafficking activity.
Symptoms and Signs
Symptoms are typically apparent from birth or early infancy and reflect widespread multisystem involvement.
Causes and Risk Factors
I-cell disease is a genetic condition and is not caused by lifestyle or environmental factors.
Diagnosis and Investigations
Diagnosis combines clinical recognition, biochemical testing, and genetic confirmation.
Disease Severity and Risk Stratification
I-cell disease is not formally staged; clinicians instead track the degree of multisystem involvement to guide supportive management.
Standard Treatment Options
There is currently no enzyme replacement or gene therapy specifically approved for I-cell disease; management centers on coordinated supportive and symptomatic care.
Advanced and Emerging Treatment Options
Disease-modifying treatment for I-cell disease remains an area of active research, given the complexity of correcting trafficking of multiple lysosomal enzymes.
Cellular Therapy
Hematopoietic Stem Cell Transplant
Has been attempted in select cases, with variable outcomes reported; its role in I-cell disease remains an area of ongoing clinical evaluation.
Research Approaches
Enzyme Trafficking Correction Research
Early research is exploring strategies to bypass or correct the underlying enzyme tagging defect, though no approach has reached clinical approval.
Biomarkers and Precision Medicine
Biochemical markers support diagnosis and help characterize the broad enzyme trafficking defect.
When a Second Opinion May Be Important
Given the rarity and complexity of I-cell disease, a second opinion from an experienced metabolic genetics center can be valuable.
Clinical Trials and Research
Prognosis and Key Outcome Factors
I-cell disease is a severe condition with significant multisystem involvement from early infancy; outcomes depend on the degree of cardiac, respiratory, and skeletal complications and access to coordinated specialist care.
Supportive Care and Living With Mucolipidosis II
Given the multisystem nature of I-cell disease, coordinated supportive care across multiple specialties is central to management.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by I-cell disease with medical report review, second opinion coordination with metabolic genetics specialists, and guidance on accessing multidisciplinary specialist centers.
Get a free case reviewFrequently Asked Questions
I-cell disease is a severe inherited disorder caused by GNPTAB gene mutations that impair the tagging of multiple lysosomal enzymes, leading to widespread accumulation of undegraded material and multisystem involvement from early infancy.
Coarse facial features, skeletal abnormalities, growth failure, and joint stiffness are often apparent from birth or early infancy.
Yes. It is inherited in an autosomal recessive pattern caused by mutations in the GNPTAB gene.
Diagnosis combines elevated serum lysosomal enzyme levels, skeletal imaging showing dysostosis multiplex, and confirmatory GNPTAB genetic testing.
The skeleton, heart, respiratory system, and development are commonly affected, reflecting the broad impact of the underlying enzyme trafficking defect.
There is currently no enzyme replacement or gene therapy specifically approved; management focuses on coordinated multidisciplinary supportive care.
It has been attempted in select cases with variable outcomes, and its role remains an area of ongoing clinical evaluation.
Both result from GNPTAB-related enzyme trafficking defects, but I-cell disease (Mucolipidosis II) is more severe and earlier-onset, while Mucolipidosis III is milder and slower-progressing.
Care typically involves genetics, cardiology, pulmonology, orthopedics, nutrition, and developmental specialists working together.
Yes. CancerFax can help review medical and genetic reports, coordinate second opinions with metabolic genetics specialists, and explore access to multidisciplinary specialist centers, including cross-border coordination where relevant.
Navigating an I-Cell Disease Diagnosis?
CancerFax can help you connect with metabolic genetics specialists and coordinate multidisciplinary care.